Altered radiotherapy fractionation: an opportunity not to be missed (Q40846572)

24 September 2017

1 reference

title

Altered radiotherapy fractionation: an opportunity not to be missed (English)

1 reference

adaptive radiation therapy

24 September 2017

main subject

0 references

author name string

Benson RJ

series ordinal

1

1 reference

24 September 2017

Burnet NG

series ordinal

2

1 reference

24 September 2017

publication date

1 January 1998

1 reference

24 September 2017

1 reference

24 September 2017

volume

10

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

150-154

1 reference

The EORTC hyperfractionation trial

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

The American Society of Therapeutic Radiologists Presidential Address: October 1981. Potential for improving survival rates for the cancer patient by increasing the efficacy of treatment of the primary lesion

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers?

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Improved survival with preoperative radiotherapy in resectable rectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Radiation therapy in Ewing's sarcoma: An update of the CESS 86 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

The clinical status of Tpot as a predictor? or why no tempest in the Tpot!

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Accelerated treatment and radiation myelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Costs of conventional radical radiotherapy versus continuous hyperfractionated accelerated radiotherapy (CHART) in the treatment of patients with head and neck cancer or carcinoma of the bronchus. Medical Research Council CHART Steering Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Good manners for the pharmaceutical industry

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Radiobiologically based assessments of the net costs of fractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2898%2980054-X

7 January 2021

10.1016/S0936-6555(98)80054-X

Identifiers

DOI

1 reference

24 September 2017

1 reference